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1 These two authors contributed equally to this studAn engineered zinc ﬁnger protein (eZFP) was isolated from a library based on its ability to activate
expression of the endogenous insulin gene in HEK-293 cells. Using a panel of insulin promoter con-
structs, the eZFP was shown to act through the variable number of tandem repeat (VNTR) region
located 365 base pairs upstream of the transcription start site. The eZFP also activated expression
of the IGF2 gene that lies close to INS on chromosome 11p15. These results demonstrate that the INS-
VNTR controls expression of the insulin and IGF2 genes and provide a mechanistic explanation for
previous studies that demonstrated an association between INSVNTR genotypes and placental levels
of IGF2.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In humans the insulin gene (INS) is located on chromosome
11p15 ﬂanked by the tyrosine hydroxylase (TH) and insulin-like
growth factor 2 (IGF2) genes. Expression of insulin is dependent
on several cis-acting regulatory sequences located within 300–
350 base pairs upstream of the transcription start site, which bind
b-cell restricted and ubiquitous transcription factors [1]. These fac-
tors include, amongst others, the homeodomain protein Pdx1, the
leucine zipper protein MafA and the basic helix loop helix protein
NeuroD1/b2 that forms a heterodimer with the ubiquitous basic
helix loop helix factor E47, and members of the bZIP (CREB/ATF)
family.
The human insulin gene also contains variable numbers of tan-
dem 14 bp repeats with the consensus sequence 50 TCTGGGGA-
GAGGGG located upstream of the promoter at 365 bp from the
start site [2]. Known as the variable number of tandem repeat
(VNTR) region, these sequences can adopt an altered structure,
which has been characterised as a quadriplex involving interac-
tions between the G residues on the top strand [3]. Three classes
of VNTR alleles have been identiﬁed based on the number of re-
peats of the 14 bp sequence: class I (20–63 repeats); class II (64–chemical Societies. Published by E
ty).
y.139 repeats) and class III (140–210 repeats) [4]. Susceptibility to
type 1 diabetes has been mapped to this locus, (IDDM2), with
the highest risk conferred by the class I alleles [5]. The function
of the VNTR is unclear. It is present only in primates, where it
may affect expression of the insulin gene in thymic epithelial cells.
The increased levels of insulin in the thymus may promote efﬁcient
deletion of autoreactive T-cells for proinsulin and immune toler-
ance to a key antigen implicated in type 1 diabetes [6].
There have been data around for more than 30 years describing
expression of insulin in non-pancreatic tissue. Although initially
the subject of some controversy (reviewed in [7]), there is now
strong supporting evidence for low level expression in a variety
of tissues including isolated cells of the brain [8] as well as thymus
[9]. We were interested in the epigenetic mechanisms that under-
lie the extrapancreatic expression of insulin and utilised an engi-
neered zinc ﬁnger protein (ZFP) as a tool to investigate potential
mechanisms.
Engineered ZFPs are synthetic proteins that contain modular
Cys2His2 zinc ﬁnger domains, each of which has been engineered
to recognise a speciﬁc DNA triplet [10]. A typical ZFP contains
around 3–6 such domains recognising an extended DNA sequence
containing from 9–20 bp. An engineered ZFP can contain additional
protein sequences that allow it to activate or repress gene expres-
sion, while zinc ﬁnger nucleases can be used to directly modify the
DNA and thus change speciﬁc bases [11] or facilitate integration of
long DNA sequences into speciﬁc chromosomal locations [12,13].lsevier B.V. All rights reserved.
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activator that targets the insulin gene. This ZFP was shown to acti-
vate the insulin gene in HEK-293 and HepG2 cells through the
VNTR region. The data also provide direct evidence that the VNTR
regulates expression of the adjacent IGF2 gene.
2. Materials and methods
2.1. Cell culture
HEK-293 (human embryonic kidney) and HepG2 (human hepa-
toma) cells were cultured in DMEM containing 10% (vol.vol.) foetal
calf serum. INS-1 (rat insulinoma) cells were cultured in RPMI con-
taining 10% foetal calf serum, 2 mM L-glutamine, 1 mM sodium
pyruvate, 10 mM HEPES and 50 lM b-mercaptoethanol.
2.2. Plasmids and transfections
The insulin promoter plasmids have previously been described
[14]. Transfections, using LipofectamineTM were also performed as
previously described [14,15]. Essentially, cells to be transfected
were grown to 50–80% conﬂuence and complexes were prepared
using a DNA (lg) to LipofectamineTM (ll) ratio of 1:8. The DNA to
be transfected was diluted in Opti-MEM I reduced serummedium
(Invitrogen) and mixed gently. In a separate bijou, LipofectamineTM
was diluted in the same volume of Opti-MEM I as the DNA and
the two mixtures combined. The resultant solution was mixed
gently and incubated at room temperature for 30 min. The com-
plexes were added to cells in growth medium without serum,
rocked gently to mix and incubated at 37 C overnight. The follow-
ing day growth medium containing twice the normal concentra-
tion of serum was added without removing the transfection
cocktail. Using these conditions we observed that the HEK-293
tended to ﬂoat off the dish. To overcome this problem the wells
of the plate were coated with ﬁbronectin. Despite this there was
some loss of cells that led to inter-experimental variations in trans-
fection efﬁciency.
2.3. Reporter assays
Chloramphenicol acetyl transferase (CAT) assays were per-
formed in assay buffer containing 100 mM Tris pH 7.8, 6 mM
MgCl2, 10 mM KCl, 1 mM coenzyme A, 7.5 mM ATP and 10 lCi 3H
acetate. Cell lysates were added and the samples incubated at
37 C for 3 h. The samples were then extracted with benzene and
the radioactivity counted. Renilla luciferase was measured as pre-
viously described [15].
2.4. QPCR
Cells were harvested 48 h after transfection and total RNA pre-
pared using the TRIzol reagent. RNA was treated with DNase1 and
analysed using TaqMan PCR probe sets available from Applied Bio-
systems. Samples were ampliﬁed in a thermal cycler (Roche Light-
cycler 480). Quantiﬁcation of the target gene was calculated
relative to the constitutively expressed standard gene, GAPDH,
using the 2DCT method [16], where DCT = (CT,Target  CT,GAPDH).
The results were analysed for statistical signiﬁcance using an un-
paired student’s T test.
3. Results
An engineered ZFP was isolated from a library of ZFPs on the ba-
sis of its ability to activate the endogenous insulin gene in HEK-293
cells (Sangamo Biosciences Inc.). The ZFP, hereafter designated INS-ZFP, contained a 3-ﬁnger DNA-binding domain and the nuclear
translocation signal from SV40 large T antigen linked to VP64, a
tetramer of the transactivation domain of the VP16 protein from
Herpes simplex. A plasmid harbouring the INS-ZFP was transfected
into a number of cell lines. In untransfected HEK-293 and HepG2
cells the levels of insulin mRNA were undetectable. In cells tran-
siently transfected with the INS-ZFP plasmid substantial levels of
insulin mRNA could be detected (Fig. 1). Although the relative
amount of insulin mRNA was well below those detected in human
pancreas, for both HEK-293 and HepG2 cells the levels were in the
range observed for islet amyloid polypeptide (IAPP) or somato-
statin in human pancreas (data not shown). These results could
be explained by the INS-ZFP directly mediating its effects on the
insulin gene or by an indirect effect on the expression of transcrip-
tion factors that are known to regulate the insulin gene. To address
these possibilities HEK-293 cells were transfected with INS-ZFP
and a number of b-cell transcription factors and islet markers were
measured by Q-PCR. Under conditions whereby INS-ZFP elicited an
almost 12-fold increase in insulin mRNA relative to GAPDH levels,
there was no detectable expression of Pdx1, b2, MafA, Ngn3 or
Nkx6.1 (Fig. 1). In addition there was no detectable expression of
other pancreatic markers including glucagon, somatostatin, IAPP,
and amylase. Under similar conditions a Pdx1-VP16 construct
[17] that is known to induce expression of insulin in liver [18]
had no effect on the insulin gene and other pancreatic markers,
although it did stimulate expression of the endogenous Pdx1 gene
(35-fold relative to GAPDH). These results suggested that INS-ZFP
was mediating its effects directly on the insulin gene.
To map the DNA sequences that were responsive to INS-ZFP a
series of insulin promoter constructs were used [14,19]. In HEK-
293 cells INS-ZFP elicited a 120-fold increase in the pBCins-1995
construct (Fig. 2). The effect of the INS-ZFP on promoter activity
was also studied in the INS-1 b-cell line, in order to establish
whether the presence of b-cell transcription factors might enhance
or modulate the effects of the INS-ZFP. In INS-1 cells INS-ZFP in-
creased the activity pBCins-1995 by 20-fold (Fig. 2). There was
no signiﬁcant effect on the pBCins-339, pBCins-279 or pBCins-
258 constructs in either cell line. These results suggest that INS-
ZFP mediates its effects on the insulin promoter through sequences
that lie between 339 and 1995. To map the region further, a
construct, pBC-1274, was employed. INS-ZFP stimulated the activ-
ity of this construct in both HEK-293 (120-fold) and INS-1 (7-fold)
cells (Fig. 3). These results further mapped the responsive region to
sequences between 339 and 1279 that contained the VNTR.
Deletion of the VNTR or replacement of the VNTR with unrelated
sequences completely abolished the effect of INS-ZFP (Fig. 3). Col-
lectively, these data indicated that INS-ZFP mediated its effects on
the human insulin gene through the VNTR. This is in keeping with
the predicted binding site for the INS-ZFP (50 GACTGGGGA), which
occurs throughout the VNTR region.
Finally, it was discovered that INS-ZFP also activated transcrip-
tion of the adjacent IGF2 gene (Fig. 4). This effect could be seen in
HEK-293 cells, which expressed very low levels of IGF2, but not in
the HEPG2 cell line that expressed high basal levels of IGF2.4. Discussion
The length of the INSVNTR has been associated with type 1 [5]
and type 2 [20] diabetes, polycystic ovary syndrome [21], size at
birth [22] and latent autoimmune diabetes in adults (LADA) [23].
The mechanisms are not well understood but are likely to involve
differential effects of the VNTR on the expression of INS in b-cells,
thymus and other tissue [6,24,25]. Transfection studies in b-cell
lines using whole fragments of insulin gene harbouring mutations
in regions that include the VNTR [26], or insulin gene reporter con-
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Fig. 1. INS-ZFP stimulates insulin gene expression in HEK-293 and HepG2 cells. HEK-293 (A) or HepG2 (B) cells were transfected with 5 lg of plasmid INS-ZFP. Cells were
harvested 48 h later and insulin mRNA levels quantiﬁed by QPCR. The results, normalised to GAPDH, represent the mean ± S.E.M. of 6–9 individual transfections where
**P < 0.005 and ***P < 0.0001. HEK-293 cells were also transfected with 5 lg of plasmid ZFP-INS (C) or plasmid Pdx-1VP16 (D). Cells were harvested 48 h later and the levels of
the indicated mRNAs were quantiﬁed by QPCR. The results, normalised to GAPDH, represent the mean ± S.E.M. of 3–6 individual transfections.
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Fig. 2. INS-ZFP stimulates insulin promoter activity through sequences that lie upstream of 339. The schematic (A) shows the 50 region of the human insulin promoter
contained within the indicated chloramphenicol acetyl transferase (CAT) constructs, with the position of the VNTR highlighted. HEK-293 and INS1 cells were co-transfected
with 250 ng of the indicated CAT reporter construct, 5 ng of Renilla luciferase reporter plasmid, 250 ng of ZFP-INS and pcDNA3.1 to make a total DNA quantity of 1 lg. After
48 h, the transfected cells were harvested and assayed for CAT and Renilla luciferase enzyme activity. The CAT activity, normalised against Renilla luciferase activity, is
expressed relative to that measured in the absence of the ZFP-INS for each reporter plasmid used. The data shown represent the mean ± S.E.M. of at least three separate
experiments performed in triplicate.
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Fig. 3. INS-ZFP stimulates insulin promoter activity through the VNTR region. The schematic (A) shows the 50 region of the human insulin promoter contained within the
indicated chloramphenicol acetyl transferase (CAT) constructs, with the position of the VNTR highlighted. In pBCinsDIP, the VNTR sequences have been deleted, and in
pBCins.IP the VNTR sequences have been replaced with a similar sized fragment from bacteriophage k. HEK-293 (B) and INS-1 (C) cells were co-transfected with 250 ng of the
indicated CAT reporter construct, 5 ng of Renilla luciferase report plasmid, 250 ng of ZFP-INS and pcDNA3.1 to make a total DNA quantity of 1 lg. After 48 h, the transfected
cells were harvested and assayed for CAT and Renilla luciferase enzyme activity. The CAT activity, normalised against Renilla luciferase activity, is expressed relative to that
measured in the absence of the INS-ZFP for each reporter plasmid used. The data shown represent the mean ± S.E.M. of at least three separate experiments performed in
triplicate.
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Fig. 4. INS-ZFP stimulates IGF2 expression in transfected HEK-293 cells. HEK-293 (A) or HepG2 (B) cells were transfected with 5 lg of plasmid INS-ZFP. Cells were harvested
48 h later and IGF2 mRNA levels quantiﬁed by QPCR. The results, normalised to GAPDH, represent the mean ± S.E.M. of 6–9 individual transfections where ***P < 0.0001.
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further support to the view that the INSVNTR is transcriptionally
active. Collectively these results suggest that the INSVNTR may
play a role in regulating expression of the insulin gene. Here, using
an engineered zinc ﬁnger protein, we demonstrate a direct effect of
the INSVNTR on insulin mRNA levels and promoter activity.
Is there an endogenous b-cell counterpart of the INS-ZFP that
acts to control expression of the insulin gene? There are numerous
zinc ﬁnger proteins expressed in the b-cell. In a preliminary study
we investigated the role of EGR-1 [28], (which exhibits strong pro-
tein sequence similarity to the zinc ﬁnger domain of INS-ZFP), MAZ
[27] and KLF11 [29]. Of these three we were able to conﬁrm [30] a
stimulatory effect of MAZ on the pBC1995 construct but could de-tect no effect of EGR-1 or KLF11 (data not shown). It will now be
important to determine whether INS-ZFP or its endogenous coun-
terparts can activate the insulin gene in cells, such as the rare
endocrine cells of the gut [31] that might have importance in the
treatment of diabetes mellitus.
The engineered zinc ﬁnger protein also provided novel insights
into the regulation of the IGF2 gene. It has previously been shown
that in normal term placenta the median IGF2 steady-state mRNA
levels is signiﬁcantly greater in samples from women with class I
than those with class III VNTR alleles [32]. Here, using an engi-
neered zinc ﬁnger protein, we extend these ﬁndings by showing
for the ﬁrst time that that the INS VNTR can directly affect expres-
sion of the IGF2 gene.
L.A. Ferguson et al. / FEBS Letters 583 (2009) 3181–3186 3185Regulation of the IGF2 gene is complex. In adults its expression
is ubiquitous with high levels in liver and heart [33]. It is also ex-
pressed in the developing embryo where it plays a key role in foe-
tal growth and development. IGF2 and the adjacent H19 gene lie in
a region of chromosome 11 that is subject to imprinting. Thus IGF2
is expressed on the paternal chromosome, while the adjacent H19
gene, that encodes a noncoding RNA, for which the function is not
well understood, is expressed on the maternal chromosome [34].
Expression of these two genes is dependent on the activity of an
imprinting centre (IC) that binds the zinc ﬁnger protein CTCF
[35]. One possibility is that the INS-ZFP might be acting on IGF2
through the IC sequences. However, this is unlikely since there
are no consensus INS-ZFP binding sites (50 GACTGGGGA) within
the IC. Interestingly, the INS gene contains a single perfect CTCF
consensus binding site (Hay and Docherty, unpublished), suggest-
ing a potential mechanism whereby CTCF could form a looping
structure bringing the INSVNTR into proximity to the IGF2 regula-
tory hub on the paternal chromosome. This possibility is currently
being investigated. There is also evidence that the INS gene is im-
printed, being expressed under some circumstances like IGF2 from
the paternal chromosome [36–38]. This is further in keeping with
direct effects of the INSVNTR on the IGF2 gene, and warrant further
studies on how expression of IGF2, which controls foetal develop-
ment and islet growth could explain the association between INS-
VNTR length and metabolic diseases [33].
In summary, we describe here the properties of an engineered
zinc ﬁnger protein that switches on the insulin gene in non b-cells
and may provide important insights into the epigenetic events that
underpin tissue speciﬁc expression of the insulin gene. The INS ZFP
also activates expression of the IGF2 gene, prompting further stud-
ies on the network of factors that control formation of the INS-
IGF2-H19 chromatin hub.
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